1. Home
  2. CISO vs GDTC Comparison

CISO vs GDTC Comparison

Compare CISO & GDTC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo CISO Global Inc.

CISO

CISO Global Inc.

HOLD

Current Price

$0.48

Market Cap

24.5M

Sector

Technology

ML Signal

HOLD

Logo CytoMed Therapeutics Limited

GDTC

CytoMed Therapeutics Limited

HOLD

Current Price

$1.66

Market Cap

24.8M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CISO
GDTC
Founded
2015
2018
Country
United States
Singapore
Employees
N/A
N/A
Industry
Computer Software: Prepackaged Software
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
24.5M
24.8M
IPO Year
N/A
2023

Fundamental Metrics

Financial Performance
Metric
CISO
GDTC
Price
$0.48
$1.66
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
817.2K
79.1K
Earning Date
11-13-2025
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$27,743,266.00
$573,193.00
Revenue This Year
N/A
$5.37
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
63.03
52 Week Low
$0.30
$1.50
52 Week High
$3.84
$4.05

Technical Indicators

Market Signals
Indicator
CISO
GDTC
Relative Strength Index (RSI) 31.80 40.26
Support Level $0.46 $1.71
Resistance Level $0.60 $2.12
Average True Range (ATR) 0.06 0.12
MACD 0.02 -0.01
Stochastic Oscillator 15.07 25.81

Price Performance

Historical Comparison
CISO
GDTC

About CISO CISO Global Inc.

CISO Global Inc provides cybersecurity services. The services are used to protect client's data, financial information, intellectual property, and business reputation. The services include penetration testing, security remediation, compliance auditing, vulnerability assessment, and others. Geographically, the company operates in U.S., Chile and All other countries. The maximum revenue is generated from U.S.

About GDTC CytoMed Therapeutics Limited

CytoMed Therapeutics Ltd is a pre-clinical biopharmaceutical company focused on harnessing its proprietary technologies to create novel cell-based immunotherapies for the treatment of human cancers. The company's segment include: the business of innate immune cell-based immunotherapy, pluripotent stem cell-based therapy and undertaking the research and development of immune cell and stem cell-based therapy; and the business of processing and banking of cells including cord blood stem cells, research and development on cord blood derived cell-based therapy. Geographically, the company operates in Singapore and Malaysia which is the majority revenue generator.

Share on Social Networks: